Recently, Eli Lilly announced the long-term therapeutic effects of its investigational IL-13 inhibitor, lebrikizumab, in patients with moderate to severe atopic dermatitis.
This article summarized the latest R&D progress of Dopamine hydrochloride, the mechanism of action for Dopamine hydrochloride, and the drug target R&D trends for Dopamine hydrochloride.
Recently, Abbisko Therapeutics announced that its independently developed next-generation EGFR Exon20ins inhibitor ABSK112 has received approval from the NMPA of China for clinical trial applications.
Medicines that inhibit COX can alleviate inflammation and pain symptoms. Medications that inhibit Cyclooxygenase activity, such as aspirin, have been available to the public for around 100 years.
Recently, KangaBio announced that its independently developed "Tumor-Specific Recombinant IL-12 Fc Fusion Protein for Injection" (pipeline code: KGX101) clinical trial application (IND) has been officially approved by the U.S. FDA.
This article summarized the latest R&D progress of Diroximel fumarate, the Mechanism of Action for Diroximel fumarate, and the drug target R&D trends for Diroximel fumarate.
Recently, Johnson & Johnson announced the results of its Phase 3 clinical trial for its anti-IL-23 antibody Tremfya (guselkumab) in treating moderate to severe ulcerative colitis (UC).
Recently, AbbVie announced that the National Medical Products Administration (NMPA) of China has approved two new indications for its JAK inhibitor, upadacitinib extended-release tablets.
This article summarized the latest R&D progress of Doxofylline, the Mechanism of Action for Doxofylline, and the drug target R&D trends for Doxofylline.
The US FDA has approved Biosyngen's BST02 for clinical trials. This cutting-edge TIL liver cancer therapy is a pioneer in cellular and gene therapy and is the first universal liver cancer TIL treatment to progress to the clinical stage.